1 day ago

Summit Therapeutics (SMMT) Stock Hits 52-Week Low After FDA Rejects Lung Cancer Drug

TLDR SMMT traded near $11.70 premarket Monday, down about 17% to a new 52-week low. The FDA issued a Complete Response Letter for ivonescimab in EGFR-mutated lung cancer. The agency wants proof of an overall survival benefit that clears the statistical bar. Jefferies sees limited downside, and Barclays cut its target to $18 from $20. [...]

The post Summit Therapeutics (SMMT) Stock Hits 52-Week Low After FDA Rejects Lung Cancer Drug appeared first on Blockonomi.

Source: Blockonomi →